IP Library Granted Patent US 7,745,606
Granted Patent B2
US 7,745,606 · App. 10/741,720 · Granted Jun 29, 2010

Immunostimulatory sequence oligonucleotides and methods of using the same

Assignee: Dynavax Technologies Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,745,606
App. No.
10/741,720
Granted
Jun 29, 2010
Kind
B2
Abstract

The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.

Claims (10)

1. An isolated polynucleotide consisting essentially of: 5′TCGAACGTTCGAAGATGATGAT-3′ (SEQ ID NO: 171).

2. A method of modulating an immune response in an individual comprising administering to an individual an immunomodulatory polynucleotide according to claim 1 in an amount sufficient to modulate an immune response in said individual.

3. A method of increasing interferon-gamma (IFN-γ) in an individual, comprising: administering an immunomodulatory polynucleotide according to according to claim 1 to said individual in an amount sufficient to increase IFN-γ in said individual.

4. A method of increasing interferon-alpha (IFN-α) in an individual, comprising: administering an immunomodulatory polynucleotide according to claim 1 to said individual in an amount sufficient to increase IFN-α in said individual.

5. A method of ameliorating a symptom of an infectious disease in an individual, comprising: administering an effective amount of an immunomodulatory polynucleotide according to claim 1 to the individual, wherein an effective amount is an amount sufficient to ameliorate a symptom of said infectious disease.

6. A method of ameliorating a symptom of an IgE-related disorder in an individual, comprising: administering an effective amount of an immunomodulatory polynucleotide according to claim 1 to an individual having an IgE-related disorder, wherein an effective amount is an amount sufficient to ameliorate a symptom of said IgE-related disorder.

7. The isolated polynucleotide of claim 1 wherein polynucleotide comprises at least one phosphorothiorate linkage.

8. The isolated polynucleotide of claim 7 wherein all the nucleotide linkages are phosphorothiorate linkages.

9. The isolated polynucleotide of claim 8 wherein the polynucleotide consists of the sequence 5′-TCGAACGTTCGAAGATGATGAT-3′ (SEQ ID NO: 171).

10. The isolated polynucleotide of claim 1 wherein the polynucleotide consists of the sequence 5′-TCGAACGTTCGAAGATGATGAT-3′ (SEQ ID NO: 171).

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 14, 2021
From: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
To: DYNAVAX TECHNOLOGIES CORPORATION
Reel/Frame 056252/0515 →
SECURITY INTEREST Recorded Feb 22, 2018
From: DYNAVAX TECHNOLOGIES CORPORATION
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 045441/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2004
From: DINA, DINO; FEARON, KAREN L.; MARSHALL, JASON
To: DYNAVAX TECHNOLOGIES CORPORATION
Reel/Frame 014673/0018 →
Continuity (4)
Provisional Application 6043612200 · Dec 23, 2002
Provisional Application 6044788500 · Feb 13, 2003
Provisional Application 6046754600 · May 1, 2003
Related Publication 20060058254A1 · Mar 16, 2006